Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential ...

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by ...

The application is supported by data from the pivotal phase 3 ARANOTE trial. Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of darolutamide (Nubeqa) in ...

Active surveillance is effective for low-risk prostate cancer, with low metastasis and mortality rates over 10 years. The study underscores the need for improved risk stratification to minimize ...

Aquablation is a versatile treatment for benign prostatic hyperplasia, suitable for prostates of any size or shape, unlike other therapies limited by anatomical variations. Contraindications include ...

Urologists need oncologists to provide systemic therapy insights and manage immune-related adverse events in combination therapy. Oncologists rely on urologists for expertise in local disease ...

The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, ...

The AMPLIFY trial will evaluate Cu-SAR-bisPSMA PET/CT for detecting biochemical recurrence in prostate cancer, enrolling 220 patients starting early 2025. Previous trials, COBRA and PROPELLER, ...

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular ...

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor ...

Route of administration impacts patient compliance and convenience, influencing the choice of PD-1/PD-L1 agents. Duration of therapy affects patients' quality of life and is a key consideration in ...

Curium and PDRadiopharma are partnering to develop PSMA-targeting theranostics for prostate cancer in Japan. Lu-PSMA-I&T is in a phase 3 trial for metastatic castration-resistant prostate cancer, ...